5N

52north Creators Of Neutrocheck®

www.52north.health link_icon

Company Research Report: 52 North Health Ltd.



Company Overview



  • Name: 52 North Health Ltd

  • Mission: To help people live better lives through innovation, collaboration, and the use of cutting-edge technology centered around patients, carers, doctors, paramedics, and nurses.

  • Founded: 2018

  • Founders: No information is available

  • Key People:

  • Umaima Ahmad - Chief Executive Officer

  • Dr. Mireia Crispin - Chief Digital Officer

  • Dr. Saif Ahmad - Chief Scientific & Medical Officer

  • Dr. Nikki Weckman - Chief Technology Officer

  • Dr. Anna Wilson - Head of Operations

  • Dr. Ama Frimpong - Head of Product Development

  • Jason Higgins - Head of Digital Development

  • Aislinn O'Farrell - Clinical Affairs Associate

  • Dr. Laura Burzynski - Senior Scientist

  • Samuel Rebollo Díaz - Senior Developer

  • Don Steel - Senior Product Design Engineer

  • Isabelle Comber - Founder's Associate

  • Joe Chalk - Digital Project Manager

  • Hemalatha Jayabal - KTP Immunoassay Development Scientist

  • Dr. Amanda Wooding - Investor Director

  • Prof Sir Leszek Borysiewicz - Non-Executive Director

  • Tanya Humphreys - Board Observer

  • Headquarters: Ideaspace West, The Hauser Forum, 3 Charles Babbage Road, Cambridge CB3 0GT, UK

  • Number of Employees: No information is available

  • Revenue: No information is available

  • Known For: Developing affordable, innovative healthcare technologies that enhance care for cancer patients and integrate with digital platforms.


Products



  • Neutrocheck®:

  • Description: A low-cost finger prick blood test and digital platform designed to provide rapid and reliable results at home, helping doctors to identify patients at risk of neutropenic sepsis.

  • Key Features:

  • Quick at-home testing

  • Integration with digital platforms

  • Provides peace of mind and safer care for people living with cancer

  • Addresses critical problems in current chemotherapy pathways by minimizing unnecessary visits to A&E


Recent Developments



  • Product Launches: No new product launches are specifically mentioned.

  • New Features: No specific new features to existing products are mentioned.

  • Partnerships and Recognition:

  • Neutrocheck® recognized under the UK Government's IDAP Scheme

  • 52 North Health selected for various accelerator programs such as Cedars Sinai Accelerator Program, Novartis' digital accelerator BIOME UK HealthHub, and TMCi Digital Health Accelerator

  • Featured as an Innovate UK Success Story and on HolonIQ's Europe Health Tech 200

  • Awards and recognition include:

  • Best Product Idea at IEEE Sensors Conference

  • MedTech Company of the Year

  • Tech for Good Award

  • Significant funding rounds and grants, including a £1.2m collaboration grant, $1.4m from SBRI, and several awards from Innovate UK and MedTech Accelerator

  • First venture investment from Macmillan Cancer Support

  • Scientific Publications:

  • Paper on the Neutrocheck® solution published in "Trends in Biotechnology"


Given these insights, 52 North Health Ltd is positioned as a pioneering entity in healthcare technology, offering innovative solutions that aim to make significant impacts on patient care, particularly for those undergoing cancer treatments.